GAD2 and cerebellar ataxia: These bioenergetic shifts paralleled significant clinical recovery, as evidenced by a reduction in the Scale for the Assessment and Rating of Ataxia (SARA) score from 17 to 12, and were further accompanied by a decrease in the anti-GAD65 antibody index.